Summary
The glycoprotein precursor of the highly cytopathic Zairian virus HIV1-NDK synthesized in CEM leukemic cells displayed a molecular mass of 140 kDa (gp 140) as compared to the 160 kDa of gp 160 of HIV1-LAV prototype strain. This precursor was cleaved to produce a smaller than prototype extracellular envelope glycoprotein (gp 100) and a transmembrane component with a usual size (gp 41). Immunoprecipitates from tunicamycin-treated infected cells demonstrated the presence of a non-glycosylated precursor of 100 kDa for HIV1-LAV prototype strain and 90 kDa for HIV1-NDK. Digestion of labeled precipitates with a mixture of endoglycosidase F and glycopeptidase F reduced the size of HIV1-LAV gp 160 and gp 120 to 100 and 60 kDa, respectively, while HIV1-NDK gp 140 and gp 100, after treatment with the same enzymes, displayed an apparent molecular mass of 90 kDa and 55 kDa, respectively. From these data we conclude that HIV1-LAV gp 120 and HIV1-NDK gp 100 differ both in their proteic moiety (60 kDa and 55 kDa, respectively) and in their carbohydrate moiety (60 kDa and 45 kDa, respectively). These differences could not be deduced from the available gene sequences of the two viruses. A chimeric virus containing the first 124 amino acid residues of the envelope glycoprotein coded by HIV1-LAV sequence and the rest by HIV1-NDK displayed normal size envelope glycoproteins, demonstrating the involvement of this N-terminal sequence in the alteration of the molecular mass characteristic of HIV1-NDK gp 140 and gp 100. Finally, characterization of thegag gene products from both strains demonstrated that HIV1-NDK p 18 and p 15 have a slower electrophoretic mobility as compared to its HIV1-LAV counterparts. Therefore, structural properties of HIV1-NDKenv andgag products, reflected by their unusual electrophoretic mobilities, may be responsible for HIV1-NDK biological properties.
Similar content being viewed by others
References
Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Brun-Vezinet F, Rouzioux C, Rozenbaum W, Montagnier L (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk of acquired immunodeficiency syndrome. Science 220: 868–871
Cheng-Mayer C, Seto D, Levy J (1991) Altered host range of HIV-1 after passage through various human cell types. Virology 181: 288–294
Ellrodt A, Barré-Sinoussi F, Le Bras P, Nugeyre MT, Palazzo L, Rey F, Brun-Vezinet F, Rouzioux C, Segond P, Caquet R, Montagnier L, Chermann JC (1984) Isolation of a new human T-lymphotropic retrovirus (LAV) from a married couple of Zairians, one with AIDS, the other with prodromes. Lancet i: 1383–1385
Yahi N, Fantini J, Baghdiguian S, Chermann JC (1991) Human T-lymphoblastoid cells selected for growth in serum-free medium provide new tools for study of HIV replication and cytopathogenicity. J Virol Methods 34: 193–207
Fenouillet E, Gluckman JC, Bahraoui E (1990) Role of N-linked glycans of envelope glycoproteins in infectivity of human immunodeficiency virus type 1. J Virol 64: 2841–2848
Fisher AG, Ensoli B, Looney D, Rose A, Gallo RC, Saag MS, Shaw GM, Hahn BH, Wong-Staal F (1988) Biologically diverse molecular variants within a single HIV-1 isolate. Nature 334: 444–447
Gruters RA, Neefjes JJ, Tersmette M, De Golde RE, Tulp A, Huisman HG, Miedema F, Ploegh HL (1987) Interference with HIV-induced syncitium formation, viral infectivity by inhibitors of trimming glycosidase. Nature 330: 74–77
Hansen JE, Clausen H, Nielson C, Telgbjaerg LS, Hansen LL, Nielsen CS, Dabelsteen E, Mathiesen L, Hakomori S, Nielsen JO (1990). Inhibition of human immunodeficiency virus (HIV) infection in vitro by anti-carbohydrate monoclonal antibodies peripheral glycosylation of HIV envelope glycoprotein gp 120 may be a target for virus neutralization. J Virol 64: 2833–2840
Heifetz A, Keenan RW, Elbein AD (1979) Mechanism of action of tunicamycin on the UDP-GlcNAc: dolichylphosphate GlcNAc-1-phosphate transferase. Biochemistry 18: 2186–2192
Hirsch I, Spire B, Tsunetsugu-Yokota Y, Neuveut C, Sire J, Chermann JC (1990) Differences in cytopathogenicity of human immunodeficiency viruses type 1 (HIV-1) are not determined by long terminal repeats (LTR). Virology 177: 759–763
Hunter E, Swanstrom R (1990) Retrovirus envelope glycoproteins. Curr Top Microbiol Immunol 157: 187–253
Ivey-Hole M, Clarck RK, Rosenberg M (1991) The N-terminal 31 amino acids for human immunodeficiency virus type 1 envelope protein gp 120 contain a potential gp 41 contact site. J Virol 65: 2682–2685
Kalyanaraman VS, Rodriguez V, Josephs S, Gallo RC, Sarngadharan MG (1990) Differential viral gene expression and its effect on the biological properties of the cell clones of an HIV-1-infected cell line. Virology 177: 380–383
Leonard CK, Spellman W, Riddle L, Harris RJ, Thomas JN, Gregory TJ (1990) Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp 120) expressed in Chinese hamster ovary cells. J Biol Chem 265: 10373–10382
Mac Dougal JS, Kennedy MS, Sligh JM, Cort SP, Mawle A, Nicholson JK (1986) Binding of HTL VIII/LAV to T4+ T-cells by a complex of the 110 K viral protein and the T4 molecule. Science 231: 382–385
Morikawa Y, Moose JP, Wilkinson AJ, Jones IM (1991) Reduction in CD4 binding affinity associated with removal of a single glycosylation site in the external glycoprotein of HIV-2. Virology 189: 853–856
Rey MA, Spire B, Dormont D, Barré-Sinoussi F, Montagnier L, Chermann JC (1984) Characterization of the RNA dependent DNA polymerase of a new human T lymphotropic retrovirus (lymphadenopathy associated virus). Biochem Biophys Res Comm 121: 126–133
Rey F, Barré-Sinoussi F, Schmidtmayerova H, Chermann JC (1987) Detection and titration of neutralizing antibodies to HIV using an inhibition of the cytopathic effect of the virus on MT4 cells. J Virol Methods 16: 239–249
Rey MA, Krust B, Laurent A, Guétard D, Montagnier L, Hovanessian AG (1989) Characterization of an HIV-2 related virus with a smaller sized extracellular envelope glycoprotein. Virology 173: 258–267
Rey F, Donker G, Hirsch I, Chermann JC (1991) Productive infection of CD4+ cells by selected HIV strains ist not inhibited by anti-CD4 monoclonal antibodies. Virology 181: 165–171
Spire B, Zachar V, Gobet M, Rey F, Barré-Sinoussi F, Galibert F, Chermann JC, Hampe A (1988) Molecular characterization of a highly cytopathic strain of the human immunodeficiency virus type 1. In: Giraldo G, Beth-Giraldo E, Clumeck N, Gharbi MR, Kyalwazi SK, de Thé G (eds) AIDS and associated cancers in Africa. Karger, Basel, pp 246–252
Spire B, Sire J, Zachar V, Rey F, Barré-Sinoussi F, Galibert F, Hampe A, Chermann JC (1989) Nucleotide sequence of HIV1-NDK, a highly cytopathic strain of the human immunodeficiency virus. Gene 81: 275–284
Spire B, Hirsch I, Neuvent C, Sire J, Chermann JC (1990) The env gene is not directly related to the highly cytopathogenicity of an HIV1 variant. Virology 177: 756–758
Sodroski J, Goth WC, Rosen C, Campbell K, Haseltine WA (1986) Role of the HTLVIII LAV envelope in syncitium formation and cytopathy. Nature 322: 470–474
Stephens PE, Clements G, Yarranton GT, Moore JP (1990) A chink in HIV's armour. Nature 343: 219
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yahi, N., Fantini, J., Hirsch, I. et al. Structural variability ofenv andgag gene products from a highly cytopathic strain of HIV-1. Archives of Virology 125, 287–298 (1992). https://doi.org/10.1007/BF01309645
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01309645